Novartis expands oncology pipeline with $1.5bn Myricx Bio acquisition
Novartis is acquiring Myricx Bio for up to $1.5 billion to gain control of a new NMT inhibitor payload platform, but the lead antibody-drug conjugates have not yet entered human trials.